ReviewFrontiers in medicine2026
Artificial intelligence in three-dimensional total-body photography for skin cancer surveillance.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial intelligence is often used in studies that detect skin cancer, but most work uses images of selected lesions. These images are useful for classification. However, they do not fully match real screening situations. In lesion surveillance, clinicians need to inspect many lesions across the whole body and monitor whether lesions change over time. Three-dimensional total-body photography is able to capture a wider skin surface and can support lesion selection, lesion triage, risk assessment, and follow-up comparison. This approach gives artificial intelligence more opportunity to analyze the patient beyond one selected lesion. This Mini Review discusses recent evidence on artificial intelligence-assisted three-dimensional total-body photography for skin cancer surveillance. In current applications, this approach is also used in automated triage and lesion detection, multimodal risk prediction, phenotype extraction, and longitudinal tracking. The reviewed papers show early progress, but the evidence remains limited. Skin tone reporting, workflow integration, dataset transparency, false-positive and false-negative harm, cost, and equity remain key adoption issues. The objective is to focus on the shift from selected-lesion classification to whole-body imaging. Clinical value should not be judged only by lesion-level accuracy, but also by whether artificial intelligence-assisted three-dimensional total-body photography can improve patient-level surveillance across the whole skin surface and over time. Stronger prospective, longitudinal, workflow, cost, and equity evidence is still needed before routine clinical adoption in practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.